

**Smelyanskaya M.V.,**  
*Candidate of Medical Sciences,  
Senior Research Scientist, Leading Researcher  
of immune rehabilitation laboratory,  
SU «Institute of Microbiology and Immunology  
named after I.I. Mechnikov National Academy of Medical Sciences of Ukraine»*

**Kashpur N.V.,**  
*Candidate of Biological Sciences,  
Senior Research Scientist of immune rehabilitation laboratory,  
SU «Institute of Microbiology and Immunology  
named after I.I. Mechnikov National Academy of Medical Sciences of Ukraine»*

**Peremot S.D.,**  
*Candidate of Medical Sciences,  
Senior Research Scientist, Leading Researcher  
of immune rehabilitation laboratory,  
SU «Institute of Microbiology and Immunology  
named after I.I. Mechnikov National Academy of Medical Sciences of Ukraine»*

**Volynskiy A.Yu.,**  
*Doctor of Medical Sciences,  
Head of immune rehabilitation laboratory,  
SU «Institute of Microbiology and Immunology  
named after I.I. Mechnikov National Academy of Medical Sciences of Ukraine»*

## APPLICATION AGILENT 2100 TO DETERMINE THE PROTEIN COMPOSITION OF THE LIPOSOME VACCINE

Today liposomal formulations of drugs occupied a niche in clinical practice and will soon be in high demand in the pharmaceutical market. The authors proposed to use an Agilent 2100 to determine the percentage inclusion of viral protein into liposomes when creating influenza vaccines. The device allows to obtain electropherograms for each sample and the image that mimics the separation in the gel, as well as a table that shows the size, mass and molar concentrations for each of the fragments latched. Use of internal markers makes it easy to compare the results of the separation of dif-

ferent samples and accurately determine whether there are similar proteins and in what concentrations in different samples. This allows you to quickly and with a high enough resolution to share vaccine proteins, and automatically analyzes the data obtained by fixing the presence of various proteins and determining their size and concentration. Also hold control incorporating proteins in liposomes with different ways to vaktsin.Vse is largely facilitates and accelerates data analysis. We consider it appropriate to use Agilent 2100 comprehensive assessment of the quality of liposomal influenza vaccine.